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Abstract: 
Binding of vinculin to adhesion plaque proteins is restricted by an intramolecular association of vinculin’s head 
and tail regions. Results of previous work suggest that polyphosphoinositides disrupt this interaction and 
thereby promote binding of vinculin to both talin and actin. However, data presented here show that 
phosphatidylinositol 4,5-bisphosphate (PI4,5P2) inhibits the interaction of purified tail domain with F-actin. 
Upon re-examining the effect of PI4,5P2 on the actin and talin-binding activities of intact vinculin, we find that 
when the experimental design controls for the effect of magnesium on aggregation of PI4,5P2 micelles, 
polyphosphoinositides promote interactions with the talin-binding domain, but block interactions of the actin-
binding domain. In contrast, if vinculin is trapped in an open confirmation by a peptide specific for the talin-
binding domain of vinculin, actin binding is allowed. These results demonstrate that activation of the actin-
binding activity of vinculin requires steps other than or in addition to the binding of PI4,5P2.  
 
Article: 
Vinculin, a 117-kDa component of microfilament-associated cell junctions (1), is a modular protein composed 
of a 95-kDa N-terminal, globular head domain connected by a short proline-rich region to a 30-kDa tail domain 
(reviewed in Ref. 2). Vinculin has an essential role in embryogenesis (3, 4) and regulatory roles in adhesion, 
spreading, and motility of cells in culture (5-10). Vinculin probably functions by interacting with particular 
structural and regulatory proteins found at focal contacts and zonulae adherens (11). Biochemical experiments 
with purified proteins show that the binding sites on vinculin for talin (12), F-actin (13), acidic phospholipids 
(14), and vasodilator-stimulated phosphoprotein (15), and sites for protein kinase C-mediated phosphorylation 
(16, 17), are blocked by the intramolecular association (K d ∼ 50 nM) of the head (V h) and tail (V t) regions 
(12). Therefore, regulation of the head-tail interaction to expose cryptic ligand binding and regulatory sites is 
hypothesized to be critical for recruitment of vinculin to sites of cell adhesion and/or for vinculin-dependent 
assembly of focal adhesion complexes (13). Elucidation of the factors that regulate the head-tail interaction is 
central to understanding how events at the cell surface are expressed ultimately in the activities of molecules 
directly responsible for the functions of focal adhesion plaques.  
 
Evidence from in vitro experiments shows that acidic phospholipids in general (16), or specifically PI4,5P2 
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(18) block the interaction of purified head and tail domains and act on intact vinculin to expose the binding sites 
for talin onV h (18) and for F-actin on V t(16, 18). This observation provides a mechanistic link between cell 
surface receptors that modulate the synthesis of PI4,5P2, a signaling molecule (19) and vinculin, a structural 
molecule involved in assembling a focal adhesion plaque and mediating anchorage to the actin cytoskeleton.  
 
Here we provide new information that modifies the proposed role of PI4,5P2 in activation of vinculin. In 
particular, we report that occupancy of the lipid-binding sites in purified tail domain prevents occupancy of the 
actin-binding sites. The effect of PI4,5P2 on the interaction of purifiedV t with F-actin had not been examined in 
previous studies. Therefore, to evaluate the apparent inconsistency of our result with the proposed role of 
PI4,5P2 on the actin binding activity of vinculin, we have used a novel peptide probe of vinculin conformation 
to re-assess the effects of acidic phospholipids, including polyphosphoinositides, on the actin- and talin-binding 
activities of vinculin. We find that when the experiments are controlled for the effect of MgCl2 on the 
aggregation of PI4,5P2 micelles, the results support a modified model in which the role of PI4,5P2 is to expose 
the talin-binding site on vinculin while blocking the actin-binding site.  
 
EXPERIMENTAL PROCEDURES 
Protein Purification 
Chicken smooth muscle vinculin and its 95-kDa head fragment were purified (14, 20, 21) and stored at 4 °C in 
TEEAN (10 mM Tris-HCl, pH 7.5, 1 mM EGTA, 0.1 mM EDTA, 150 mM and 3 mMNaN3), 0.5% βME, 2 × 
protease inhibitor mixtures, PIC I and II. PIC I was added from a 1,000 × stock containing 1 mg/ml leupeptin, 2 
mg/ml antipain, 10 mg/ml benzamidine, 10 KIU/ml aprotinin in H2O. PIC II (1,000 ×) contains 1 mg/ml 
chymostatin, 1 mg/ml pepstatin in dimethysulfoxide. Vinculin was dialyzed against H2O, 0.5% βME containing 
2 × PIC I and II before its use in pVR binding experiments containing phospholipids. Rabbit skeletal muscle 
actin was purified as described previously (22) but with an additional gel exclusion chromatography step (23). 
Purified G-actin was stored in buffer A (2 mMTris-HCl, pH 7.5, 0.2 mM CaCl2, 0.2 mM ATP, and 0.5 mM 
βME).  
 
GST- and 6·His-tagged Fusion Proteins 
GST/V884–1066 was constructed and purified as has been described (12) and stored at 4 °C in TEEAN. For 
experiments requiring untagged vinculin tail fragment, V884–1066 was expressed as a 6-histidine (His)-tagged 
fusion protein. Construction of 6-His/V884–1066 involved polymerase chain reaction amplification of the 
appropriate region of the chick embryo vinculin cDNA (24) using in-frame primers. The forward and reverse 
primers contained NdeI and XhoI sites, respectively. The amplified product was ligated into pCR2.1 vector 
(Invitrogen, San Diego, CA) according to the manufacturer’s instructions, except that recombinants were 
transformed into competentEscherichia coli DH5α cells. Recombinant plasmid was digested with NdeI and 
XhoI to yield the insert fragment containing the polymerase chain reaction-amplified coding region and flanking 
vector sequence. The fragments were gel-purified using the Qiagen gel extraction kit (Chatsworth, CA) and 
ligated into the NdeI and XhoI sites of the pET-15b vector (Novagen, Madison, WI). As described in the 
manufacturer’s instructions (pET System Manual; Novagen), 6·His/V884–1066 was expressed, purified, and 
then cleaved with thrombin to remove the 6·His tag. V884–1066 was dialyzed against TEEAN containing 0.5% 
βME and 2 × PIC I and II and quantified spectrophotometrically (E m 
280
 = 18,350) at 280 nm.  
 
Peptide Synthesis 
The pVR peptide (KKKSTGGFDDVYDLARRVSSALTTTLVATRPK) with and without biotin added to the N 
terminus was synthesized using an Applied Biosystems 430 peptide synthesizer, purified by high pressure liquid 
chromatography, and sequenced by automated Edman degradation at the Biosynthesis and Sequencing Facility, 
Johns Hopkins University School of Medicine (Dept. Biological Chemistry), Baltimore, MD. Biotinylated pVR 
was characterized by mass spectrometry at the JHU School of Medicine (Dept. Pharmacology) Mass 
Spectrometry Center, Baltimore, MD.  
 
Phospholipid Vesicles 
Phosphatidylcholine, PI, and phosphatidylserine were purchased as chloroform stocks from Avanti Polar Lipids 
(Alabaster, AL) and stored at −20 °C. PI4P and PI4,5P2 were obtained as lyophilized powders from Sigma and 
were resuspended in distilled H2O, 0.5% βME, and stored (4 °C) for use in assays. PI3P, PI3,4P2, and PI3,4,5P3 
were purchased from Matreya, Inc. (Pleasant Gap, PA) as vacuum-dried powders and then resuspended in 
chloroform for storage at −20 °C.  
 
For the preparation of phosphatidylcholine, PI, and phosphatidylserine small unilamellar vesicles, chloroform 
stocks of these phospholipids were dried under N2 and then swollen at 5 mg/ml in distilled H2O, 0.5% βME, 
and then sonicated (30 min, 25 °C) in a Branson bath sonicator at the highest power setting. Small unilamellar 
vesicles containing both PI and PI4,5P2at the desired ratios were prepared by adding the required amount of 
PI4,5P2 (in distilled H2O, 0.5% βME) to a known amount of dried PI and then sonicating as described. PI3P, 
PI3,4P2, and PI3,4,5P3 were dried under N2 and resuspended in H2O, 0.5% βME before sonication (30 min, 
25 °C). Likewise, solutions of PI4P and PI4,5P2 were sonicated (30 min, 25 °C) before use in assays. 
Phospholipid concentrations were determined by inorganic phosphate analysis using the Ames method (25).  
 
Actin Polymerization 
Unless indicated otherwise, actin polymerization was induced by the addition of 100 mM KCl and 2 mM MgCl2 
from a concentrated stock solution as described previously (13). For F-actin binding assays containing lipid, the 
MgCl2 concentration was reduced to 2 μM to eliminate background sedimentation of vinculin and vinculin tail 
fragment. For experiments in low magnesium, actin polymerization was initiated by adding 100 mM KCl and 
0.1 μM sonicated (30 s, 25 °C) F-actin seed (polymerized 2 h, 25 °C by the addition of 100 mM KCl and 0.1 
mM MgCl2 to a solution of 5 μMG-actin containing buffer A, 0.2 mM ATP, and 1 mM EGTA) to the reaction 
mix (26).  
 
Precomplexing of pVR to Streptavidin-Alkaline Phosphatase 
To complex pVR with streptavidin-conjugated alkaline phosphatase (SaAP), 4 μM biotinylated-pVR was 
incubated (1 h, 25 °C) with 20 units/ml SaAP (Boehringer-Mannheim) in a 100-μl reaction mix. After 
incubation, 5 μl of saturated (0.22 mg/ml) biotin was added to the reaction mix and then incubated (0.5 h, 25 °C) 
to block the remaining biotin-binding sites of SaAP. The pVR·SaAP complex was diluted 1/40 for use on 
Western blots.  
 
Western Blotting and Detection of Biotinylated pVR 
Samples were resolved by SDS-PAGE (10%), transferred to nitrocellulose (Schleicher & Schuell) (27), and 
blocked with 10% BLOTTO in Tris-buffered saline (TBST; 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 
0.05% Tween 20). Blots containing immobilized vinculin and vinculin head fragment were probed (1 h, 25 °C) 
with SaAP·pVR complexes, washed (4 × 10 min, 25 °C) with TBST, and then treated with Nitroblue tetrazolium 
chloride and 5-bromo-4-chloro-3-indoyl phosphate (Sigma) in 0.1 mMTris-HCl (pH 9.5), 0.1 M NaCl, and 5 
mMMgCl2 for colorimetric detection of SaAP·pVR complexes bound to either immobilized vinculin or V h. 
Methods specific to individual experiments are described in the figure legends.  
 
Isolation and Analysis of Complexes with Biotinylated pVR 
Complexes with biotinylated pVR were isolated by incubating (0.5 h, 25 °C, with inversion) assay mixtures 
with steptavidin(Sa)-agarose beads (Novagen) followed by low speed (2,000 rpm × 4 min) centrifugation. Equal 
volumes of the pellet and supernatant fractions were subjected to SDS-PAGE (10% polyacrylamide gel) 
analysis (28) and the amount of target protein bound to Sa-agarose·pVR complexes was determined by 
Coomassie Blue staining of the gels. For relative quantitation, stained gels were dried, scanned, and analyzed 
densitometrically with the NIH Image program.  
 
RESULTS 
Effect of Polyphosphoinositides and Other Acidic Phospholipids on Binding of Vt to Actin Filaments  
PI4,5P2presented in micellar form, blocks the interaction of purified vinculin tail (V884–1066) with F-actin 
(Fig.1 A, lanes 1–8). Although the standard buffer for actin polymerization includes 2 mM MgCl2, experiments 
with micelles of pure PI4,5P2 were done in 0.002 mM Mg
2+
because 2 mM Mg
2+
 causes mixtures ofV t and 
PI4,5P2 to sediment in the absence of actin (Fig. 1 A, lanes 9–12). Reduction of the MgCl2 concentration from 2 
mMto 2 μM eliminated this problem (compare Fig.1 A, lanes 11–14 and lanes 3,4, 7, and 8).  
 
 
Figure 1  
Effect of pure PI4,5P2micelles and PI4,5P2/Triton mixed micelles on the interaction of Vt with F-actin. A, in a 100-μl reaction 
mix containing 3.2 mm Tris-HCl pH 7.1, 0.2 mm ATP, 100 mm KCl, 0.2 mmCaCl2, 30 mm NaCl, 0.2 mm EGTA, 0.02 mm EDTA, 
and 0.5 mm βME; purified V884–1066 (V t, 2 μm) was incubated (2 h at 25 °C) with 5 μm F-actin in the presence or absence of 100 
μm pure PI4,5P2 micelles (as indicated above each lane) and at either 2 mm or 2 μm MgCl2 (as noted above each gel). After 
incubation, the reaction mixes (100 μl) were sedimented at 95,000 × g in a Beckman Airfuge and equal volumes of pellet (P) and 
supernatant (S) fractions were resolved by SDS-PAGE. In the presence of pure PI4,5P2micelles there is a marked inhibition of V t 
binding to F-actin (compare lanes 1 and 2 withlanes 5 and 6). At 2 mmMgCl2, V t sediments to the same level in the absence of F-actin 
(lanes 11 and 12) as it does when F-actin is present (lanes 9 and 10) in the reaction mix; however, in the absence of both PI4,5P2and 
F-actin, V t remains in the supernatant (lanes 13 and 14). Reduction of the MgCl2 concentration to 2 μm eliminates the background 
sedimentation of V t (lanes 7and 8). B, as described in A,V t was assayed for F-actin binding activity at 2 μm MgCl2 and over a range 
of lipid (pure PI4,5P2 micelles, PI4,5P2/Triton mixed micelles, or phosphatidylcholine/small unilamellar vesicle) concentrations. The 
relative amounts of V t in the pellet and supernatant fractions were quantified by densitometric analysis of Coomassie Blue stained 
gels. 
 
Presentation of PI4,5P2 in the form of mixed micelles with Triton X-100 also inhibited interaction of V t with F-
actin (Fig. 1 B). Inhibition of the interaction ofV t with actin by PI4,5P2 presented either in micellar form or as 
mixed micelles with Triton X-100, is dependent on the concentration of lipid (Fig. 1 B). Phosphatidylcholine at 
up to 100 μM has no effect on F-actin binding by vinculin tail (Fig. 1 B). Analysis of other phospholipids 
revealed that PI4,5P2/Triton X-100 mixed micelles (>200 μM), PI3,4P2 (30 μM), PI3,4,5P3 (30 μM), and 
phosphatidylserine (400 μM) inhibited completely the binding of purified vinculin tail to F-actin (data not 
shown).  
 
Effect of PI4,5P2 on the Actin-binding Activity of Vinculin  
Because inhibition of the binding ofV t to actin by PI4,5P2 is not obviously consistent with a role of PI4,5P2 in 
exposing a functional actin-binding site on vinculin, we wanted to confirm the effects of acidic phospholipids 
on the conformational state of vinculin by assaying for co-sedimentation of vinculin with F-actin in the presence 
of either PI4,5P2/Triton X-100 mixed micelles (18) or pure PI4,5P2 micelles (16). When the assay was 
controlled for the effect of MgCl2 on the aggregation and sedimentation of PI4,5P2 micelles, there was no co-
sedimentation of vinculin with F-actin in the presence of micelles composed of pure PI4,5P2 (Fig. 2, A versus 
B). Divalent cations induce aggregation of PI4,5P2 micelles (29), thus proteins bound to PI4,5P2 micelles co-
sediment with cation-induced PI4,5P2 aggregates. Although the Mg
2+
concentration does not affect the 
sedimentation of mixed micelles of PI4,5P2 and Triton X-100, when these mixed micelles were examined at 
more than one concentration, they also failed to induce dose-dependent co-sedimentation of vinculin with F-
actin even when the PI4,5P2 concentration was raised to 100 μM (Fig. 2 C).  
  
 
Figure 2  
A, effect of pure PI4,5P2micelles on the interaction of full-length vinculin with F-actin. As described in Fig. 1 A, purified vinculin (1 
μm) was incubated (2 h, 25 °C, and 2 μm MgCl2) with 5 μm F-actin in the presence or absence of either 20 μm or 100 μm PI4,5P2 
micelles as indicated above each lane. After incubation, the reaction mixes (100 μl) were sedimented at 95,000 × g in a Beckman 
Airfuge and equal volumes of pellet (P) and supernatant (S) fractions were resolved by SDS-PAGE. Comparison oflanes 1–4 with 5–
12 shows that in the presence of either 20 μm or 100 μm pure PI4,5P2 micelles there is no detectable induction of vinculin binding to 
F-actin. B, effect of 2 mmMgCl2 on the sedimentation of vinculin in the presence of pure PI4,5P2 micelles. As has been described, 1 
μm vinculin was assayed for F-actin binding activity at 2 mm MgCl2 and in the presence or absence of either 20 μm or 100 μm pure 
PI4,5P2 micelles as indicated above each lane. Under these conditions, sedimentation of vinculin is as high in the absence of F-actin 
(lanes 3, 4, 7, 8, 11, and 12) as it is in the presence of F-actin (lanes 1, 2, 5, 6, 9, and10). Reduction of the MgCl2 concentration to 2 
μm eliminates this high background sedimentation of vinculin (compare with Fig. 2 A). In the absence of both PI4,5P2 and F-actin, 
vinculin does not sediment when the MgCl2 concentration is 2 mm (Fig.2 B, lanes 3 and 4). C,effect of PI4,5P2/Triton mixed micelles 
on the interaction of vinculin with F-actin. Native vinculin was assayed as described in A for F-actin binding activity in the presence 
of 0, 10, 50, and 100 μm PI4,5P2/Triton X-100 mixed micelles, as indicated above each lane, at 2 mmMgCl2. PI4,5P2/Triton X-100 
mixed micelles do not induce vinculin co-sedimentation with F-actin. Note that there is no background sedimentation of vinculin at 2 
mmMgCl2 in the presence of PI4,5P2/Triton X-100 mixed micelles (lanes 7, 8, 11, 12, 15, and16). 
 
Characterization of Peptide pVR as a Probe of the Open Conformation of Vinculin 
As an independent means of assessing the effect of acidic phospholipids on exposure of the actin- and talin-
binding sites of vinculin, we have used a peptide (KKKSTGGFDDVYDLARRVSSALTTTLVATRPK) isolated 
from a phage-displayed random peptide library based on binding of phage to immobilized vinculin (30). This 
peptide, called pVR, inhibits binding of talin, but not α-actinin or paxillin, to immobilized vinculin, suggesting 
that the peptide binds at or near the talin-binding domain of vinculin. Control peptides bearing the same net 
positive charge as pVR but having distinct amino acid sequences do not bind to vinculin (30). Previous work 
(30) demonstrated that although pVR binds to vinculin that has been adsorbed to polystyrene, polyvinylidene 
difluoride, or nitrocellulose (Fig.3 B), it does not bind to vinculin in solution (Fig. 3 A). The pVR binding site, 
located in the first 258 amino acid residues of the N-terminal head domain of vinculin, is made accessible for 
solution-based assays by removing the C-terminal tail domain of vinculin, residues 857–1066 (Fig. 3 A) (30), 
suggesting that the intramolecular head-tail interaction of vinculin blocks the binding site for pVR. That pVR is 
a specific probe for the open conformation of native vinculin is further supported by the finding that addition of 
purified vinculin tail domain to the reaction mix inhibits binding of pVR to vinculin head fragment in a dose-
dependent fashion (K i ∼ 0.4 μM) (Fig. 4 A). This experiment shows that pVR binding occurs specifically to a 
site onV h that is masked by V t in the closed conformation of vinculin rather than to a new site created by 
unfolding of V h after proteolytic removal ofV t. Conversely, pVR is able to compete binding ofV t to V h with 
∼K i = 0.3 μM (Fig. 4 B) indicating that V t and pVR interact at or near the same site on V h. Collectively, these 
observations validate the use of pVR as a probe to identify the open conformation of full-length vinculin in 
vitro.  
  
 
Figure 3  
A, binding of pVR to full-length vinculin, 95-kDa vinculin head, and vinculin tail (V884–1066) in solution. Vinculin (0.5 μm), 95-kDa 
proteolytic head fragment (V h, 0.5 μm), or vinculin tail fragment (V t, 2 μm) was incubated (1 h, 25 °C, 50 μl reaction) with 5 
μmbiotinylated-pVR in PBS and 0.01% BSA. Complexes with biotinylated pVR were isolated as described under “Experimental 
Procedures,” and the amount of vinculin (lanes 1 and 2),V h (lanes 3 and 4), andV t (lanes 5 and 6) co-sedimenting with Sa-
agarose·pVR complexes was assessed also as described. In the absence of pVR, there was no sedimentation of vinculin, V h, or V t with 
Sa-agarose beads (not shown). B, analysis of pVR binding to immobilized vinculin, V h , andV t . Purified vinculin (4.5 μg;lanes 1, 4, 
and 7),V h (3 μg; lanes 2, 5, and8), and V t (5 μg; lanes 3,6, and 9) were resolved by SDS-PAGE (10%), transferred to nitrocellulose 
and blocked as described under “Experimental Procedures.” Lanes 4–6 were incubated (1 h, 25 °C) with 0.1 μm biotinylated pVR 
precomplexed with SaAP and then developed as described under “Experimental Procedures.” Binding of SaAP-bound pVR to 
immobilized vinculin andV h was blocked by pre-incubation (1 h, 25 °C) with 10 μm nonbiotinylated pVR (not shown), and SaAP 
alone does not bind to immobilized vinculin, V h, orV t (lanes 7–9).   
 
 
 
 
 
Figure 4  
A, evaluation of pVR as a specific probe for the open conformation of vinculin in vitro.V h (0.3 μm) was incubated (1 h, 25 °C, 50-μl 
reaction) with a range (0.25–8 μm) of GST-V884–1066 (GST-V t) concentrations in PBS and 0.01% BSA before adding 1 μm (final 
concentration) biotinylated pVR to the reaction mix. Complexes with pVR were isolated as described, and the relative amounts ofV h 
co-sedimenting with Sa-agarose·pVR complexes in the presence (lanes 3 and 4, inset) or absence (lanes 1 and 2, inset) of GST-V t 
were quantified by densitometry of Coomassie Blue stained gels. The amount of V h pelleting in the absence of GST-V t represents 
100% bound.B, competition of pVR for V t binding toV h . V h (0.35 μm) was incubated (1 h, 25 °C, 50 μl reaction) with a range (0.5–
20 μm) of pVR (nonbiotinylated) concentrations in PBS and 0.01% BSA before adding 1 μmGST-V t to the reaction mix. GST·V t 
complexes were isolated by incubating (0.5 h, 25 °C, with inversion) the reaction mixes with glutathione-agarose beads (Sigma) 
followed by low speed (2,000 rpm × 4 min) centrifugation. Coomassie Blue stained gels of the resulting pellets (P) and supernatants 
(S) were analyzed by densitometry to determine the relative amounts of V hco-sedimenting with glutathione-agarose beads in the 
presence (lanes 3 and 4, inset) or absence (lanes 1 and 2, inset) of pVR. The amount of V h pelleting in the absence of pVR represents 
100% bound. 
 
Effect of Polyphosphoinositides on Exposure of the Binding Site for pVR 
Using biotinylated pVR to examine the effects of PI4,5P2 exposure of the talin- and actin-binding sites on 
vinculin, we found that in 100 mM KCl only micelles of pure PI4,5P2 (Fig. 5 A,lanes 1–8) and bilayer vesicles 
containing at least 50% PI4,5P2 (Fig. 6 B) induce a dose-dependent opening of vinculin to expose the pVR 
binding site. Mixed Triton micelles containing up to 100 μM PI4,5P2 did not activate vinculin for pVR binding 
(Fig. 5 B, lanes 9–12). To control for the possibility that pVR associates with vinculin through the mutual 
affinity of vinculin and pVR for PI4,5P2 micelles rather than through a PI4,5P2-induced exposure of the pVR 
binding site on vinculin, we examined the interaction of pVR with vinculin tail in the presence of PI4,5P2. 
Although vinculin tail contains the high affinity PI4,5P2 binding site (14), pVR does not bind to purified 
vinculin tail in the presence of PI4,5P2(Fig. 5 C, lanes 13–16). Thus, polyphosphoinositide-induced binding of 
pVR to vinculin is mediated by the specific interaction of the peptide with its binding site in vinculin head 
domain.  
  
 
 
Figure 5  
Effect of pure PI4,5P2micelles and PI4,5P2/Triton X-100 mixed micelles on the ability of vinculin to bind pVR in solution. A, 
reaction mix A (25 μl, 1.6 μm vinculin, 100 mm KCl, without lipid or with 40 μmPI4,5P2) was incubated 0.5 h at 25 °C before adding 
reaction mix B (25 μl, 4 μm biotinylated pVR, 2× PBS, and 0.02% BSA) to give a 50-μl reaction volume containing 0.8 μm vinculin, 
2 μm biotinylated pVR, 1× PBS, 0.01% BSA, and either no lipid or 20 μm pure PI4,5P2 micelles. After incubating for 1 h at 25 °C, 
complexes with biotinylated pVR were isolated as described, and the amount of vinculin (lanes 1–8) co-sedimenting with Sa-
agarose·pVR complexes was determined by SDS-PAGE of equal volumes of the supernatants (S) and pellets (P). In negative control 
reactions, nonbiotinylated pVR was used in place of biotinylated pVR as indicated by a (−) above the appropriate lanes.B, the pVR 
binding activity of native vinculin was assayed as described in A except that the final reaction mix contained 100 μm PI4,5P2/Triton 
X-100 mixed micelles instead of pure PI4,5P2 micelles (lanes 9–12). Under these conditions there is no induction of pVR binding by 
vinculin. C, as a control for PI4,5P2bridging of pVR to the lipid binding region in vinculin tail, 2 μm V884–1066 (V t) was used in 
place of vinculin in experiments containing PI4,5P2 (lanes 13–16). 
 
 
Figure 6  
A, abilities of various acidic phospholipids to induce pVR binding by vinculin. Reaction mix A (see Fig. 5 A) with or without 10 μm 
lipid (phosphatidylserine, PI, PI3P, PI4P, PI3,4P2, PI4,5P2, or PI3,4,5P3 as indicated) was incubated (0.5 h at 25 °C, 50-μl reaction). 
Reaction mix B (see Fig. 5 A) was then added, and the reaction was then incubated for 1 h at 25 °C. Complexes with biotinylated pVR 
were isolated and analyzed as described, and the relative amounts of vinculin co-sedimenting with Sa-agarose·pVR complexes were 
determined. Plotted values represent the mean of three independent determinations, and bars indicate the mean ± S.E. B, effects of 
phospholipid packing on activating vinculin to bind pVR. The pVR binding activity of native vinculin was assayed (as described for 
Fig.6 A) in the presence of either pure PI4,5P2micelles, PI4,5P2/Triton X-100 mixed micelles, or mixed vesicles of PI4,5P2 and PI (at 
the ratios indicated in the figure). C, relative ability of different polyphosphoinositides to open vinculin for pVR binding. The level of 
pVR binding by vinculin was determined (as described for Fig.6 A) at physiologic ionic strength (100 mm KCl) in the presence of 0, 
2, 5, 10, 20, and 40 μmPI3,4P2, PI4,5P2, or PI3,4,5P3. Plotted values represent the mean of three independent determinations; error 
bars indicate the plotted mean ± S.E. 
 
Among the acidic phospholipids tested, only the polyphosphoinositides (PI3,4P2, PI4,5P2, and PI3,4,5P3) 
activated vinculin for pVR binding (Fig. 6 A) when the assay was performed in at least 100 mM salt. This 
polyphosphoinositide-induced activation of vinculin is dose-dependent (Fig. 6 C) and peaks at about 40 μM 
lipid. When the concentration of polyphosphoinositide is >40 μM, the level of pVR binding by vinculin 
decreases due to an apparent interaction between pVR and polyphosphoinositide at high concentrations of 
phospholipid (data not shown). Vinculin also binds to pVR when PI4,5P2 is presented in mixed vesicles with PI. 
However, maximal activation occurs only when PI4,5P2 represents at least 50% of the vesicular lipid (Fig. 6 B).  
 
pVR Induces Actin-binding Activity in Vinculin 
The preceding results indicated that pVR could be used to determine whether vinculin in the open conformation 
can bind F-actin when the actin-binding site is not occluded by PI4,5P2. In solution, the closed conformation of 
vinculin is favored strongly because of the high affinity of the head-tail interaction and the fact that head and 
tail interact intramolecularly. However, equilibrium kinetics predicts that vinculin can be trapped kinetically in 
open form in the presence of a large molar excess of a ligand that inhibits the intramolecular head-tail 
interaction. pVR blocks the bimolecular interaction between the purified head and tail fragments of vinculin 
with aK i of ∼ 0.3 μM (Fig.4 B), consistent with the affinity (K d ∼ 0.1 μM) of pVR for vinculin head (30). 
When the concentration of pVR is raised to 6,000-fold molar excess over theK d determined for the bimolecular 
interaction of head and tail (K d ∼ 50 nM), vinculin becomes competent to bind F-actin (Fig.7). This effect of 
pVR on binding of vinculin to actin is specific because 95-kDa head fragment alone does not co-sediment with 
F-actin at similar concentrations of pVR. Sedimentation of vinculin requires the presence of both pVR and F-
actin, and sedimentation of vinculin with actin depends upon the amount of pVR present (Fig. 7).  
  
 
Effect of pVR, a competitive ligand for the head-tail interaction, on opening of vinculin for F-actin binding.Vinculin (0.44 μM) 
was incubated (1 h, 25 °C, 100-μl reaction) with 4.7 μM F-actin over a range (30–500 μM) of nonbiotinylated pVR concentrations in 
buffer A containing 2 mM MgCl2 and 100 mMKCl before sedimentation at 95,000 × g in a Beckman Airfuge. Equal volumes of 
reaction pellets (P) and supernatants (S) were resolved by gel electrophoresis (as described) and Coomassie Blue stained gels were 
analyzed by densitometry to determine the relative amounts of vinculin that co-sediment with F-actin in the presence of pVR ligand 
(lanes 3–6, inset). Vinculin does not sediment when either pVR (lanes 1 and 2, inset) or F-actin (lanes 5 and 6, inset) is absent from 
the reaction mix and proteolytic head (V h) does not co-sediment with F-actin in the presence of pVR (lanes 9 and10, inset). 
 
DISCUSSION 
We have found that micellar PI4,5P2 enables vinculin to bind pVR, but does not allow binding to F-actin. This 
result is consistent with the observation that PI4,5P2 inhibits binding of F-actin to purified V t. We also show 
that vinculin does bind F-actin when the intramolecular interaction of head and tail is displaced by an ∼6,000-
fold molar excess of pVR over theK d for the bimolecular interaction of the purified head and tail domains. 
Previous studies have shown that PI4,5P2 and several other acidic phospholipids, inhibit the bimolecular 
interaction of purified head and purified tail (16, 18). In addition, there is partial overlap of vinculin’s F-actin 
binding regions (residues 884–1012 and 1012–1066) (31, 32) and acidic phospholipid binding regions (residues 
916–970 and 1012–1066) (33,34). Therefore, it is likely that PI4,5P2 inhibits the interaction of vinculin and V t 
with F-actin by occluding the actin-binding site. Altogether, the data are consistent with a model in which 
polyphosphoinositides presented in the form of micelles displace the head domain of vinculin by binding to the 
tail domain. Ligand-binding sites in V h are unmasked, but the F-actin binding sites in V t are occluded by the 
bound phospholipid (Fig. 8). Based on earlier work (33), the tail domain of open vinculin will be partially 
buried in the hydrophobic core of the lipid micelles (Fig. 8).  
 
 
Figure 8  
Cartoon illustrating the differential effect of pVR and polyphosphoinositides on exposure of the talin- and actin-binding sites 
in vinculin. PIP2 binds to the tail domain of vinculin and disrupts the intramolecular interaction with the head domain. As a result, the 
talin-binding site inV h becomes accessible, but the actin-binding sites in V t are blocked by the bound PIP2. pVR displaces the head-
tail interaction by binding at or near the talin-binding site on V h leavingV t free to associate with F-actin. 
 
Several other actin-binding proteins are also inhibited by PI4,5P2 (35) and recent structural evidence suggests a 
common mechanism of PI4,5P2 action. The atomic structure of gelsolin indicates that polyphosphoinositides 
compete with F-actin for binding to overlapping, solvent-exposed sites on plasma gelsolin (36). Evidence also 
suggests a competitive mechanism for PI4,5P2disruption of profilin-actin (37) and destrin-actin (38) complexes.  
A possible source of the difference between our results on the effects of micellar PI4,5P2 and those reported 
previously (16) is the concentration of MgCl2 used in the buffer for actin-binding assays. We observed that 
when 2 mMMgCl2 was a component of the actin polymerization buffer (as in Ref. 16), addition of pure PI4,5P2 
micelles to the assay mix caused sedimentation of vinculin and vinculin tail in the absence of F-actin. At 
millimolar concentrations of divalent cation, PI4,5P2 micelles form large aggregates that pellet at speeds 
required to sediment F-actin (29). Under these conditions, proteins that bind to PI4,5P2 also sediment. The 
published data does not exclude the possibility that the MgCl2 effect on aggregation of PI4,5P2 micelles is a 
source of the difference between our results and those of Weekes et al.(16).  
 
Our data indicates that the physical packing of polyphosphoinositides in pure micelles is crucial for opening 
vinculin because mixed micelles of Triton X-100 and PI4,5P2 are unable to cause binding of pVR or F-actin to 
vinculin. This finding is inconsistent with an earlier report that mixed micelles containing 0.33 molecules of 
PI4,5P2/Triton micelle (10 μMPI4,5P2) activates vinculin to bind both talin and F-actin (18). In our 
experiments, there is not a dose-dependent effect of mixed micelles containing from 0.33–3 molecules of 
PI4,5P2 per micelle on co-sedimentation of actin and vinculin. Although it is possible that we have not 
reproduced exactly the conditions of the previous report, the absence of data demonstrating a dependence of 
vinculin co-sedimentation with F-actin on the amount of PI4,5P2 in the Triton micelles (18), together with the 
results presented here, argues against a role for PI4,5P2 in exposing the actin-binding activity of vinculin. This 
conclusion is strengthened by the demonstration of dose-dependent inhibition of F-actin binding to purifiedV t 
by PI4,5P2 micelles and by PI4,5P2/Triton mixed micelles.  
 
Using pVR as a probe for the talin-binding conformation of vinculin, we examined the effects of various acidic 
phospholipids on exposure of the talin-binding site on vinculin. In buffers containing at least 100 mM KCl, only 
pure micelles of the polyphosphoinositides (PI3,4P2, PI4,5P2, and PI3,4,5P3) induce a dose-dependent binding 
of pVR to vinculin. The finding that 3-phosphorylated inositol lipids can induce conformational change in 
vinculin suggests that intracellular signaling through phosphoinositide 3-kinase (to produce PI3,4P2 and 
PI3,4,5P3), along with those signals mediating PI4,5P2 levels, may also be important in vinculin activation.  
 
Evidently, differential exposure of various ligand-binding sites on vinculin can be achieved depending on the 
mechanism of conformational alteration. For example, PI4,5P2-induced changes in vinculin unmask the talin 
and pVR-binding site but block the actin-binding sites, whereas pVR-induced changes occupy the talin-binding 
site and expose the actin-binding sites (Fig. 8). The implication is that depending on the mechanism of 
activation, vinculin might be assembled into complexes that differ by virtue of which ligand-binding sites on 
vinculin are functional. This provides a potential mechanism for building functionally dissimilar protein 
complexes from the same repertoire of protein components.  
 
Currently it is thought that signal transduction events stimulate the local synthesis of PI4,5P2 at focal adhesions. 
This newly synthesized PI4,5P2 then recruits and/or opens vinculin to expose the sites for talin and F-actin, 
thereby contributing to assembly of plaque components and linkage of actin to the plasma membrane (18). 
However, our results indicate that in order for PI4,5P2-bound vinculin to bind actin, the PI4,5P2 would have to 
be hydrolyzed or displaced from vinculin. PI4,5P2 hydrolysis could occur by the action of a specific 
phospholipase or phosphatase, making the induction of vinculin’s actin-binding activity a two step process. 
Alternatively, vinculin might be activated by yet unknown mechanisms that expose both the talin- and actin-
binding activities.  
 
ACKNOWLEDGEMENTS 
We thank Jodie Franklin and Jennifer Senft for synthesis, purification, and sequencing of pVR, and Amina S. 
Woods for the mass spectrometry of biotinylated pVR.  
 
Footnotes 
 * This work was supported by research Grant GM41605 from the National Institutes of Health and by a grant 
from the Muscular Dystrophy Association.The costs of publication of this article were defrayed in part by the 
payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 
U.S.C. Section 1734 solely to indicate this fact.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
 
 
REFERENCES 
  
Geiger B., Tokuyasu K. T., Dutton A. H., Singer S. J.(1980) Proc. Natl. Acad. Sci. U. S. A. 77:4127–4131. 
  
Winkler J., Lunsdorf H., Jockusch B. M.(1996) J. Struct. Biol. 116:270–277. 
 
Barstead R. J., Waterston R. H.(1991) J. Cell Biol. 114:715–724. 
 
Weiming X., Baribault H., Adamson E. D.(1998) Development 125:327–337. 
  
Coll J.-L., Ben-Ze’ev A., Ezzell R. M., Rodriguez Fernandez J. L., Baribault H., Oshima R. G., Adamson E. D. 
(1995) Proc. Natl. Acad. Sci. U. S. A. 92:9161–9165. 
 
Volberg T., Geiger B., Kam Z., Pankov R., Simcha I., Sabanay H., Coll J.-L., Adamson E., Ben-Ze’ev A.(1995) 
J. Cell Sci. 108:2253–2260. 
  
Weiming X., Coll J.-L., Adamson E. D.(1998) J. Cell Sci. 111:1535–1544. 
 
Rodriguez Fernandez J. L., Geiger B., Salomon D., Sabanay I., Zoller M., Ben-Ze’ev A.(1992) J. Cell Biol. 
119:427–438. 
  
Rodriguez Fernandez J. L., Geiger B., Salomon D., Ben-Ze’ev A.(1993) J. Cell Biol. 122:1285–1294. 
 
  
Rodriguez Fernandez J. L., Geiger B., Salomon D., Ben-Ze’ev A.(1992) Cell Motil. Cytoskeleton 22:127–134. 
  
Goldmann W. H., Ezzell R. M., Adamson E. D., Niggli V., Isenberg G.(1996) J. Muscle Res. Cell Motil. 17:1–
5. 
 
 Johnson R. P., Craig S. W.(1994) J. Biol. Chem. 269:12611–12619. 
  
Johnson R. P., Craig S. W.(1995) Nature 373:261–264. 
 
Johnson R. P., Craig S. W.(1995) Biochem. Biophys. Res. Commun. 210:159–164. 
 
Huttelmaier S., Mayboroda O., Harbeck B., Jarchau T., Jockusch B. M., Rudiger M.(1998) Curr. Biol. 8:479–
488. 
 
Weekes J., Barry S. T., Critchley D. R.(1996) Biochem. J. 314:827–832. 
  
Schwienbacher C., Jockusch B. M., Rudiger M.(1996) FEBS Lett. 384:71–74. 
  
Gilmore A. P., Burridge K.(1996) Nature 381:531–535. 
  
McNamee H. M., Ingber D. E., Schwartz M. A.(1992) J. Cell Biol. 121:673–678. 
 
Feramisco J. R., Burridge K.(1980) J. Biol. Chem. 255:1194–1199. 
  
Groesch M. E., Otto J. J.(1990) Cell Motil. Cytoskeleton 15:41–50. 
 
Spudich J., Watt S.(1971) J. Biol. Chem. 246:4866–4871. 
  
MacLean-Fletcher S., Pollard T. D.(1980) Biochem. Biophys. Res. Commun. 96:18–27. 
 
Coutu M. D., Craig S. W.(1988) Proc. Natl. Acad. Sci. U. S. A. 85:8535–8539. 
  
Ames B. N.(1966) Methods Enzymol. 8:115–118. 
  
Pollard T. D(1983) Anal. Biochem. 134:406–412. 
  
Mumby S. M., Buss J. E.(1990) METHODS: A Companion to Methods in Enzymology 1:216–220.  
 
Laemmli U. K.(1970) Nature 227:680–685. 
  
Flanagan L. A., Cunningham C. C., Chen J., Prestwich G. D., Kosik K. S., Janmey P. A.(1998) Biophys. J. 
73:1440–1447. 
  
Adey N. B., Kay B. K.(1997) Biochem. J. 324:523–528. 
  
Johnson R. P., Craig S. W.(1995) Mol. Biol. Cell 6:341, (abstr.). 
  
Huttelmaier S., Bubeck P., Rudiger M., Jockusch B.(1997) Eur. J. Biochem. 247:1136–1142. 
 
Johnson R. P., Niggli V., Durrer P., Craig S. W.(1998) Biochemistry 37:10211–10222. 
 
Tempel M., Goldmann W. H., Isenberg G., Sackmann E.(1995) Biophys. J. 69:228–241. 
  
Janmey P. A.(1994) Annu. Rev. Physiol. 56:169–191. 
 
  
Burtnick L. D., Koepf E. K., Grimes J., Jones E. Y., Stuart D. I., McLaughlin P. J., Robinson R. C.(1997) Cell 
90:661–670. 
  
Pollard T. D., Almo S., Quirk S., Vinson V., Lattman E. E.(1994) Annu. Rev. Cell Biol. 10:207–249. 
  
Hatanaka H., Ogura K., Moriyama K., Ichikawa I., Inagaki F.(1996) Cell 85:1047–1055. 
 
 
 
